Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), and CD4/CD8 enriched, with potential immunostimulating and antineoplastic activities. Upon administration, MB-CART20.1 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies and certain melanoma cell subpopulations.

**Synonyms:** - Anti-CD20 CAR T Cells MB-CART20.1 - Autologous CD20-targeted CAR-transduced CD4/CD8 Enriched T Cells MB-CART20.1 - CD20-targeting CAR T Cells MB-CART20.1 - MB-CART20.1